Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
IPO Date: April 2, 1991
Sector: Healthcare
Industry: Biotech
Market Cap: $52.99B
Activated in VL: True
Average Daily Range
Avg Daily Range: $4.22 | 1.81%
Avg Daily Range (30 D): $9.33 | 1.65%
Avg Daily Range (90 D): $11.10 | 1.79%
Institutional Daily Volume
Avg Daily Volume: .66M
Avg Daily Volume (30 D): 1.32M
Avg Daily Volume (90 D): .95M
Trade Size
Avg Trade Size (Sh.): 64
Avg Trade Size (Sh.) (30 D): 31
Avg Trade Size (Sh.) (90 D): 28
Institutional Trades
Total Inst.Trades: 11,016
Avg Inst. Trade: $17.86M
Avg Inst. Trade (30 D): $36.73M
Avg Inst. Trade (90 D): $45.38M
Avg Inst. Trade Volume: .05M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $35.31M
Avg Closing Trade (30 D): $97.16M
Avg Closing Trade (90 D): $93.45M
Avg Closing Volume: 71.83K
   
News
Jun 7, 2025 @ 10:30 PM
Dupixent® (dupilumab) Data at Revolutionizing A...
Source: Regeneron Pharmaceuticals, Inc. And Sanofi
Jun 1, 2025 @ 3:16 PM
Temu Parent PDD, Regeneron Pharmaceutical And Burl...
Source: Lekha Gupta
May 31, 2025 @ 12:04 PM
Libtayo® (cemiplimab) Phase 3 Data in the Adjuv...
Source: Regeneron Pharmaceuticals, Inc.
May 30, 2025 @ 12:30 PM
Regeneron, Sanofi Stock Falls After Uneven Smoker'...
Source: Vandana Singh
May 30, 2025 @ 5:00 AM
Press Release: Itepekimab met the primary endpoint...
Source: N/A
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $41.77 $7.58 $8.54
Diluted EPS $39.33 $7.27 $8.11
Revenue $ 14.09B $ 3.03B $ 3.79B
Gross Profit $ $ $
Net Income / Loss $ 4.5B $ 808.7M $ 917.7M
Operating Income / Loss $ 3.83B $ 591.7M $ 990.2M
Cost of Revenue $ $ $
Net Cash Flow $ 483.2M $ 604M $ 477.2M
PE Ratio 0.00